ANXA3 and SOCS3, as novel biomarkers for acute myocardial infarction (AMI), demonstrates significantly superior diagnostic performance compared to traditional markers CD34 and FLT3, with area under the ROC curve (AUC) exceeding 0.7, highlighting their stronger clinical relevance. This evidence concerns the gene CD34 and acute myocardial infarction.